ESPR Esperion Therapeutics Inc.

Esperion to Participate in January Investor Meetings

Esperion to Participate in January Investor Meetings

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th, 2023 in San Francisco, California.

J.P. Morgan 41st Annual Healthcare Conference

Sheldon Koenig, CEO, will be making a corporate presentation and hosting 1x1 institutional investor meetings.

Date/Time: January 11th, 2023, 1:30pm PT

Location: The Westin St. Francis Hotel in San Francisco; Georgian Room

Click to access the webcast.

LifeSci Partners 12th Annual Corporate Access Event

Sheldon Koenig, CEO, Ben Halladay, CFO, and JoAnne Foody, CMO, will be hosting 1x1 institutional investor meetings.

Date/Time: January 9-10th, 2023

Location: Beacon Grand Hotel in San Francisco

To schedule a meeting on the online system managed by LifeSci Partners, please click to register for the conference.

Esperion Therapeutics

Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit and follow us on Twitter at /EsperionInc.

Contact:

Esperion Corporate Communications



EN
13/12/2022

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results...

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours afte...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Esperion to Participate in The 2026 Citizens Life Sciences Conference ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. About Esperion TherapeuticsEsperion Th...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Mar...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expir...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such ind...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcar...

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –        – Expects Operating Expenses of Between $210 Million and $2...

January 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch